Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1956 1
1972 1
1977 1
1979 1
1985 3
1986 3
1989 1
1990 3
1992 1
1993 1
1994 2
1995 1
1997 1
1998 3
1999 2
2000 6
2001 2
2003 4
2004 4
2005 7
2006 5
2007 5
2008 9
2009 9
2010 5
2011 14
2012 17
2013 7
2014 12
2015 11
2016 19
2017 13
2018 10
2019 11
2020 7
2021 9
2022 9
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Addiction: A treatise from 1561.
Nadeau L, Valleur M. Nadeau L, et al. Addiction. 2023 Nov;118(11):2235-2241. doi: 10.1111/add.16298. Epub 2023 Jul 22. Addiction. 2023. PMID: 37482901
Enhancing CAR-T Cell Therapy with Functional Nucleic Acids.
Maru B, Nadeau L, McKeague M. Maru B, et al. Among authors: nadeau l. ACS Pharmacol Transl Sci. 2021 Nov 17;4(6):1716-1727. doi: 10.1021/acsptsci.1c00188. eCollection 2021 Dec 10. ACS Pharmacol Transl Sci. 2021. PMID: 34927006 Free PMC article. Review.
How we treat tumor lysis syndrome.
Muslimani A, Chisti MM, Wills S, Nadeau L, Zakalik D, Daw H, Huang J, Jaiyesimi I. Muslimani A, et al. Among authors: nadeau l. Oncology (Williston Park). 2011 Apr 15;25(4):369-75. Oncology (Williston Park). 2011. PMID: 21618960 Free article. Review.
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Någård M, Ah-See ML, Strauss J, Wise-Draper T, Safran HP, Nadeau L, Edenfield WJ, Lewis LD, Ottesen LH, Li Y, Mugundu GM. Någård M, et al. Among authors: nadeau l. Cancer Chemother Pharmacol. 2023 Sep;92(3):193-203. doi: 10.1007/s00280-023-04554-3. Epub 2023 Jul 2. Cancer Chemother Pharmacol. 2023. PMID: 37394627 Free PMC article. Clinical Trial.
Gambling Self-Control Strategies: A Qualitative Analysis.
Flores-Pajot MC, Atif S, Dufour M, Brunelle N, Currie SR, Hodgins DC, Nadeau L, Young MM. Flores-Pajot MC, et al. Among authors: nadeau l. Int J Environ Res Public Health. 2021 Jan 12;18(2):586. doi: 10.3390/ijerph18020586. Int J Environ Res Public Health. 2021. PMID: 33445592 Free PMC article.
197 results